Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery
Lexaria’s recent animal study on its patented DehydraTECH(TM) technology on nicotine absorption yielded ground-breaking resultsThis study builds on an earlier 2018 study that demonstrated effective delivery of nicotine to the central nervous system in a rodent studyThe study’s success will serve as the foundation for a human trial that will compare the DehydraTECH-nicotine pouch performance to leading brands Zacks Small Cap Research recently did a…